



09-29-2008

FORM PTO-1595 (modified)



IEET

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

103527244

To the Honorable Assistant Secretary and Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies) thereof.

1. Name of conveying party(ies):

SHIONOGI &amp; CO., LTD.

Additional name(s) of conveying party(ies) attached? No

3. Nature of conveyance:

☒ Assignment                      ☐ Merger  
☐ Security Agreement           ☐ Change of Name  
☐ Other \_\_\_\_\_

Execution Date: June 29, 2007

2. Name and address of receiving party(ies):

Name: ANTHERA PHARMACEUTICALS, INC.Address: 1900 South Norfolk Street, Suite 260, San Mateo, California 94403Additional name(s) & address(es) attached? No

4. Application number(s) or patent number(s): U.S. Patent No. 5,473,096, issued December 5, 1995

If this document is being filed together with a new application, the execution date of the application is: \_

A. Patent Application No.(s)  
, filedB. Patent No.(s)  
, issuedAdditional numbers attached? Yes

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: WENDEROTH, LIND & PONACK, L.L.P.  
Attn: Matthew M. Jacob, Esq.Street Address: 2033 K Street, N.W., Suite 800City: Washington, State: DC ZIP: 20006-10216. Total number of applications and patents involved: 7

7. Total fee (37 CFR 3.41). . . . . \$280.00

☒ Enclosed (Check No. 87595)  
Authorized to be charged to deposit account8. Deposit account number: 23-0975

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Matthew M. Jacob, Reg. No. 25,154  
Name of Person Signing

Signature

September 24, 2008  
DateTotal number of pages including cover sheet: 4

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information:

THIS COMMUNICATION IS NOT AUTHORIZED  
TO CHARGE ANY DEFICIENCY  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975Commissioner and Assistant Secretary of Patents and Trademarks  
Box Assignments  
Alexandria, VA 22313

09/26/2008 NJANA1 00003627 0473096

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

DOCKET NO. 93\_1152A

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

PATENT  
REEL: 021603 FRAME: 0096

<u><b>U.S. Patent No.</b></u>	<u><b>Issue Date</b></u>
5,534,533	July 9, 1996
5,597,943	January 28, 1997
5,663,405	September 2, 1997
5,760,270	June 2, 1998
5,981,778	November 9, 1999
5,817,826	October 6, 1998

# **ASSIGNMENT**

WHEREAS, We, **Shionogi & Co., Ltd.**, of 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541, Japan (hereinafter referred to as "the Assignor"), is the sole owner by Assignments from the respective inventors of the following United States Letters Patents (hereinafter referred to as "the Letters Patents"):

<u>Patent No.</u>	<u>Issue Date</u>	<u>Appln. No.</u>	<u>Filing Date</u>	<u>Title of Invention</u>	<u>Assignment</u>
5,473,096	12/05/1995	08/093,953	07/21/1993	Substituted benzoate derivatives	Recorded on 07/21/1993 under R/F 006636/0070
5,534,533	07/09/1996	08/313,890	09/28/1994	Carboxylate derivatives exhibiting phospholipase A <sub>2</sub> inhibitory activity	Recorded on 09/28/1994 under R/F 007164/0278
5,597,943	01/28/1997	08/571,698	12/13/1995	Phospholipase A <sub>2</sub> inhibitor	Recorded on 03/02/1993 under R/F 006510/0158
5,663,405	09/02/1997	08/530,763	09/19/1995	Process of producing ether-type thio-phospholipids	Recorded on 09/19/1995 under R/F 007684/0258
5,760,270	06/02/1998	08/847,771	04/23/1997	Process of producing ether-type thio-phospholipids	(same as above)
5,981,778	11/09/1999	09/045,924	03/23/1998	Process of producing ether-type thio-phospholipids	(same as above)
5,817,826	10/06/1998	08/905,943	08/05/1997	Oxazolinone derivatives having cytosolic phospholipase A <sub>2</sub> inhibitory activity	Recorded on 06/15/1995 under R/F 007699/0682

WHEREAS, **Anthera Pharmaceuticals, Inc.**, of 1900 South Norfolk Street, Suite 260, San Mateo, CA 94403 U.S.A. (hereinafter referred to as "Assignee"), is desirous of acquiring

the entire right, title and interest in and to the Letters Patents as possessed by the Assignor;

NOW, THEREFORE, in consideration of One Dollar (\$1.00) to the Assignor in hand paid, the receipt of which is hereby acknowledged, and other good and valuable consideration, the Assignor has sold, assigned and transferred, and by these presents does hereby sell, assign and transfer unto said Assignee, their entire right, title and interest in and to the Letters Patents within the United States of America and its territories, dependencies and possessions, together with the right to extend the protection of said Letters Patents to the various territorial possessions now owned or which may be hereafter acquired by the United States of America, all said rights to be held and enjoyed by the Assignee for its own use and behalf, and for the use and behalf of its successors or assigns, to the full end of the term for which said United States Letters Patents has been granted, as fully and entirely as the same would have been held and enjoyed by said Assignor if this assignment sale had not been made.

AND said Assignor, acting by its undersigned authorized representative, has reviewed the prior assignment documents referred to above and certifies to the best of its knowledge and believe that it holds the full right and interest to convey all interest herewith assigned, and that it has not executed, and will not execute any agreement in conflict therewith.

AND said Assignor further covenants and agrees that the Assignor will communicate to the said Assignee, their successors, legal representatives and assigns, any facts known to it respecting said Letters Patents and use all reasonable means to cause its employees to testify in any legal proceedings, sign all lawful papers, execute all reissue and reexamination applications, make all rightful oaths, and generally do everything possible to aid said Assignee, their successors, legal representatives and assigns, to perfect its share of the title and to obtain and enforce patent protection for said invention aforesaid.

The undersigned hereby grant the law firm of Wenderoth, Lind & Ponack, L.L.P. the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned on the date opposite the undersigned name.

SHIONOGI & CO., LTD.

Date: June 29, 2007

Motozo Shiono

By: Motozo SHIONO

Title: President

WITNESS: Mitsugu Kiyokawa  
Mitsugu KIYOKAWA

WITNESS: Hideaki Watanabe  
Hideaki WATANABE